Clinical Trial

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-23; most recent amendment 2025-05-06.
Trial Details
NCT Number NCT06479720
Lead Sponsor Mackay Memorial Hospital
Conditions Effect of Drug, Urinary Bladder, Overactive
Enrollment 300 participants
Start Date 2022-06-16
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-09